- Home
- NRXS vs XCUR Comparison
NRXS vs XCUR Comparison
Compare NRXS & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRXS
- XCUR
- Stock Information
- Founded
- NRXS 2011
- XCUR 2011
- Country
- NRXS United States
- XCUR United States
- Employees
- NRXS N/A
- XCUR N/A
- Industry
- NRXS
- XCUR Biotechnology: Pharmaceutical Preparations
- Sector
- NRXS
- XCUR Health Care
- Exchange
- NRXS Nasdaq
- XCUR Nasdaq
- Market Cap
- NRXS 25.8M
- XCUR 29.4M
- IPO Year
- NRXS 2023
- XCUR N/A
- Fundamental
- Price
- NRXS $2.99
- XCUR $4.56
- Analyst Decision
- NRXS Strong Buy
- XCUR
- Analyst Count
- NRXS 1
- XCUR 0
- Target Price
- NRXS $7.00
- XCUR N/A
- AVG Volume (30 Days)
- NRXS 1.0M
- XCUR 39.8K
- Earning Date
- NRXS 11-12-2025
- XCUR 11-13-2025
- Dividend Yield
- NRXS N/A
- XCUR N/A
- EPS Growth
- NRXS N/A
- XCUR N/A
- EPS
- NRXS N/A
- XCUR N/A
- Revenue
- NRXS $3,217,531.00
- XCUR N/A
- Revenue This Year
- NRXS $62.14
- XCUR N/A
- Revenue Next Year
- NRXS $131.87
- XCUR N/A
- P/E Ratio
- NRXS N/A
- XCUR N/A
- Revenue Growth
- NRXS 41.93
- XCUR N/A
- 52 Week Low
- NRXS $1.33
- XCUR $2.39
- 52 Week High
- NRXS $6.20
- XCUR $36.00
- Technical
- Relative Strength Index (RSI)
- NRXS 45.67
- XCUR 47.57
- Support Level
- NRXS $2.94
- XCUR $4.52
- Resistance Level
- NRXS $3.96
- XCUR $5.26
- Average True Range (ATR)
- NRXS 0.31
- XCUR 0.49
- MACD
- NRXS -0.06
- XCUR 0.01
- Stochastic Oscillator
- NRXS 12.61
- XCUR 6.06
About NRXS Neuraxis Inc.
Neuraxis Inc is a growth stage company is engaged in developing neuromodulation therapies to address chronic and debilitating conditions in children. The company is dedicated to advancing the science with its' proprietary Percutaneous Electrical Nerve Field Stimulation (PENFS) technology. The company focuses on targeted therapies for the pediatric and adolescent population suffering from disorders of gut-brain interaction (DGBIs).
About XCUR Exicure Inc.
Exicure Inc is an early-stage biotechnology company focused on developing nucleic acid therapies targeting ribonucleic acid against validated targets. It operates in a single segment which is Biotechnology.